

Pedro Pedro Rosa Rosa-Neto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1972093/publications.pdf>

Version: 2024-02-01

286
papers

13,645
citations

31976

53
h-index

31849

101
g-index

318
all docs

318
docs citations

318
times ranked

15399
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	10.2	668
2	Age- and Gender-Related Differences in the Cortical Anatomical Network. <i>Journal of Neuroscience</i> , 2009, 29, 15684-15693.	3.6	595
3	Human brain white matter atlas: Identification and assignment of common anatomical structures in superficial white matter. <i>NeuroImage</i> , 2008, 43, 447-457.	4.2	486
4	Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: Application to normal elderly and Alzheimer's disease participants. <i>NeuroImage</i> , 2009, 46, 486-499.	4.2	456
5	Revealing Modular Architecture of Human Brain Structural Networks by Using Cortical Thickness from MRI. <i>Cerebral Cortex</i> , 2008, 18, 2374-2381.	2.9	426
6	Multi-level bootstrap analysis of stable clusters in resting-state fMRI. <i>NeuroImage</i> , 2010, 51, 1126-1139.	4.2	307
7	Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 25.	6.2	285
8	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	7.7	285
9	Atlas-guided tract reconstruction for automated and comprehensive examination of the white matter anatomy. <i>NeuroImage</i> , 2010, 52, 1289-1301.	4.2	277
10	Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor β Agonist. <i>Journal of Neuroscience</i> , 2008, 28, 9287-9296.	3.6	258
11	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	30.7	235
12	[18F]FDG PET signal is driven by astroglial glutamate transport. <i>Nature Neuroscience</i> , 2017, 20, 393-395.	14.8	232
13	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	12.8	219
14	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	9.0	204
15	Astrocyte Biomarkers in Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2019, 25, 77-95.	6.7	203
16	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.4	197
17	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	7.9	186
18	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.8	174

#	ARTICLE	IF	CITATIONS
19	Age-related alterations in the modular organization of structural cortical network by using cortical thickness from MRI. <i>NeuroImage</i> , 2011, 56, 235-245.	4.2	160
20	Early-Onset Familial Alzheimer's Disease (EOFAD). <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 436-445.	0.5	160
21	Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. <i>Nature Communications</i> , 2019, 10, 4227.	12.8	157
22	Association of Apolipoprotein E ϵ 4 With Medial Temporal Tau Independent of Amyloid- β . <i>JAMA Neurology</i> , 2020, 77, 470.	9.0	154
23	¹⁸ F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020, 143, 2818-2830.	7.6	147
24	Age-Dependent Rescue by Simvastatin of Alzheimer's Disease Cerebrovascular and Memory Deficits. <i>Journal of Neuroscience</i> , 2012, 32, 4705-4715.	3.6	146
25	Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model. <i>Neurobiology of Disease</i> , 2014, 68, 126-136.	4.4	126
26	Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [¹⁸ F]-FEOBV. <i>Molecular Psychiatry</i> , 2017, 22, 1531-1538.	7.9	126
27	β -[¹¹ C]Methyl-L-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters. <i>European Neuropsychopharmacology</i> , 2006, 16, 220-223.	0.7	125
28	Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. <i>NeuroImage</i> , 2005, 25, 868-876.	4.2	122
29	In vivo quantification of neurofibrillary tangles with [¹⁸ F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 74.	6.2	120
30	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1182-1195.	0.8	119
31	Measurement of Brain Regional β -[¹¹ C]Methyl-L-Tryptophan Trapping as a Measure of Serotonin Synthesis in Medication-Free Patients With Major Depression. <i>Archives of General Psychiatry</i> , 2004, 61, 556.	12.3	116
32	Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). <i>Canadian Geriatrics Journal</i> , 2012, 15, 120-126.	1.2	114
33	Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 251.	4.8	112
34	Amyloid- β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. <i>Molecular Psychiatry</i> , 2017, 22, 306-311.	7.9	105
35	Odor identification as a biomarker of preclinical AD in older adults at risk. <i>Neurology</i> , 2017, 89, 327-335.	1.1	102
36	Mild behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, 192-199.	0.8	102

#	ARTICLE	IF	CITATIONS
37	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	10.1	99
38	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. <i>Journal of Neuroinflammation</i> , 2014, 11, 120.	7.2	89
39	Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues. <i>Progress in Neurobiology</i> , 2013, 110, 102-113.	5.7	88
40	Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 1758-1768.	8.9	85
41	Identifying incipient dementia individuals using machine learning and amyloid imaging. <i>Neurobiology of Aging</i> , 2017, 59, 80-90.	3.1	85
42	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.8	82
43	Synergistic interaction between amyloid and tau predicts the progression to dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 644-653.	0.8	79
44	INTREPAD. <i>Neurology</i> , 2019, 92, e2070-e2080.	1.1	76
45	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. <i>Frontiers in Neuroinformatics</i> , 2016, 10, 20.	2.5	73
46	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	11.6	73
47	Astrocyte Biomarkers in Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.1	70
48	Pioglitazone Improves Reversal Learning and Exerts Mixed Cerebrovascular Effects in a Mouse Model of Alzheimer's Disease with Combined Amyloid- β^2 and Cerebrovascular Pathology. <i>PLoS ONE</i> , 2013, 8, e68612.	2.5	69
49	Surgical Resection for Intractable Epilepsy in "Double Cortex" Syndrome Yields Inadequate Results. <i>Epilepsia</i> , 2002, 42, 1124-1129.	5.1	66
50	Determining Amyloid- β^2 Positivity Using 18 F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252.	5.0	65
51	Cerebrospinal fluid p-tau ₂₃₁ as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	6.1	65
52	Effects of acute nicotine on hemodynamics and binding of [11 C]raclopride to dopamine D _{2,3} receptors in pig brain. <i>NeuroImage</i> , 2003, 19, 1127-1136.	4.2	64
53	Deletion of the mu opioid receptor gene in mice reshapes the reward-aversion connectome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11603-11608.	7.1	64
54	Limbic system mGluR5 availability in cocaine dependent subjects: A high-resolution PET [11 C]ABP688 study. <i>NeuroImage</i> , 2014, 98, 195-202.	4.2	62

#	ARTICLE	IF	CITATIONS
55	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , 2017, 88, 1814-1821.	1.1	61
56	<i>In vivo</i> and <i>in vitro</i> Validation of Reference Tissue Models for the mGluR ₅ Ligand [¹¹ C]ABP688. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1538-1549.	4.3	60
57	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	7.6	60
58	Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [¹¹ C]ABP688 PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 152-162.	6.4	58
59	Î²-induced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , 2019, 10, 2353.	12.8	58
60	Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 80.	6.2	55
61	Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. <i>Neurology</i> , 2018, 90, e932-e939.	1.1	54
62	Mapping Neuroreceptors at work: on the Definition and Interpretation of Binding Potentials after 20 years of Progress. <i>International Review of Neurobiology</i> , 2005, 63, 1-20.	2.0	52
63	Transgenic Mice Overexpressing APP and Transforming Growth Factor-Î²1 Feature Cognitive and Vascular Hallmarks of Alzheimer's Disease. <i>American Journal of Pathology</i> , 2010, 177, 3071-3080.	3.8	51
64	Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. <i>Neurotherapeutics</i> , 2019, 16, 600-610.	4.4	51
65	APOEÎµ4 potentiates the relationship between amyloid-Î² and tau pathologies. <i>Molecular Psychiatry</i> , 2021, 26, 5977-5988.	7.9	51
66	Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study. <i>NeuroImage</i> , 2006, 30, 26-35.	4.2	50
67	Distinct increased metabotropic glutamate receptor type 5 (mGluR5) in temporal lobe epilepsy with and without hippocampal sclerosis. <i>Hippocampus</i> , 2013, 23, 1212-1230.	1.9	49
68	Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: Effects of the novel P-glycoprotein inhibitor tariquidar. <i>NeuroImage</i> , 2010, 49, 1406-1415.	4.2	47
69	Machine Learning in Nuclear Medicine: Part 1 Introduction. <i>Journal of Nuclear Medicine</i> , 2019, 60, 451-458.	5.0	47
70	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	3.1	47
71	Guidelines for the content and format of PET brain data in publications and archives: A consensus paper. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1576-1585.	4.3	47
72	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , 2021, 144, 3517-3528.	7.6	47

#	ARTICLE	IF	CITATIONS
73	Dissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive Impairment. PLoS ONE, 2012, 7, e47905.	2.5	47
74	Developments in Tau PET Imaging. Canadian Journal of Neurological Sciences, 2014, 41, 547-553.	0.5	45
75	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. Journal of Neuroscience, 2017, 37, 12263-12271.	3.6	44
76	Reduced resting-state functional connectivity of the basolateral amygdala to the medial prefrontal cortex in preweaning rats exposed to chronic early-life stress. Brain Structure and Function, 2018, 223, 3711-3729.	2.3	44
77	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2022, 60, 207-219.	2.3	44
78	Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease. Translational Neurodegeneration, 2018, 7, 23.	8.0	43
79	[¹⁸ F]SiFA-isothiocyanate: A New Highly Effective Radioactive Labeling Agent for Lysine-Containing Proteins. ChemBioChem, 2009, 10, 1321-1324.	2.6	42
80	Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. NeuroImage: Clinical, 2021, 31, 102733.	2.7	42
81	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ϵ 4, and Cognitive Impairment. Neurology, 2021, 96, e975-e985.	1.1	42
82	Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 1589-1600.	2.6	41
83	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.5	41
84	A multicenter comparison of [¹⁸ F]flortaucipir, [¹⁸ F]RO948, and [¹⁸ F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	6.4	41
85	β 234 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. Nature Communications, 2019, 10, 2240.	12.8	39
86	The effects of exercise on sleep quality in persons with Parkinson's disease: A systematic review with meta-analysis. Sleep Medicine Reviews, 2021, 55, 101384.	8.5	39
87	Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: An autoradiographic study. Brain Research Bulletin, 2012, 87, 406-412.	3.0	38
88	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. Trends in Neurosciences, 2014, 37, 629-641.	8.6	38
89	Superficially Located White Matter Structures Commonly Seen in the Human and the Macaque Brain with Diffusion Tensor Imaging. Brain Connectivity, 2011, 1, 37-47.	1.7	37
90	Test-retest stability of cerebral mGluR ₅ quantification using [¹¹ C]ABP688 and positron emission tomography in rats. Synapse, 2012, 66, 552-560.	1.2	37

#	ARTICLE	IF	CITATIONS
91	Imaging <i>in Vivo</i> Glutamate Fluctuations with [¹¹ C]ABP688: A GLT-1 Challenge with Ceftriaxone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1169-1174.	4.3	37
92	Inferior Longitudinal Fasciculus™ Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study. <i>Frontiers in Neuroscience</i> , 2019, 13, 875.	2.8	37
93	Morphometric network differences in ageing versus Alzheimer™s disease dementia. <i>Brain</i> , 2020, 143, 635-649.	7.6	37
94	MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. <i>Synapse</i> , 2004, 53, 222-233.	1.2	36
95	Resting State Executive Control Network Adaptations in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 993-1004.	2.6	36
96	Identification of [¹⁸ F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1737-1743.	6.4	36
97	Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to. <i>Experimental Gerontology</i> , 2018, 107, 169-177.	2.8	36
98	Association of Vascular Risk Factors With β -Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. <i>JAMA Network Open</i> , 2020, 3, e1920780.	5.9	36
99	Staging of Alzheimer™s disease: past, present, and future perspectives. <i>Trends in Molecular Medicine</i> , 2022, 28, 726-741.	6.7	36
100	Intact Memory in TGF- β 1 Transgenic Mice Featuring Chronic Cerebrovascular Deficit: Recovery with Pioglitazone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 200-211.	4.3	35
101	Mapping the amphetamine-evoked changes in [11C]raclopride binding in living rat using small animal PET: Modulation by MAO-inhibition. <i>NeuroImage</i> , 2007, 35, 38-46.	4.2	34
102	Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 334-348.	1.5	34
103	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer™s disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	6.2	34
104	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837.	6.1	34
105	PET imaging of cholinergic deficits in rats using [18F]fluoroethoxybenzovesamicol ([18F]FEOBV). <i>NeuroImage</i> , 2012, 62, 555-561.	4.2	33
106	Cholinergic Depletion in Alzheimer™s Disease Shown by [18F]FEOBV Autoradiography. <i>International Journal of Molecular Imaging</i> , 2013, 2013, 1-6.	1.3	33
107	Imaging Alzheimer's disease pathophysiology with PET. <i>Dementia E Neuropsychologia</i> , 2016, 10, 79-90.	0.8	33
108	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	3.3	33

#	ARTICLE	IF	CITATIONS
109	Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 610-617.	3.7	32
110	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2021, 16, 28.	10.8	32
111	In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD. <i>Brain Structure and Function</i> , 2016, 221, 1387-1402.	2.3	31
112	Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 577-590.	2.6	31
113	Topographic Distribution of Amyloid- β^2 , Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. <i>Neurology</i> , 2021, 96, e81-e92.	1.1	31
114	Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease. <i>Scientific Data</i> , 2015, 2, 150043.	5.3	30
115	Intermediate flortaucipir uptake is associated with $A\beta^2$ -PET and CSF tau in asymptomatic adults. <i>Neurology</i> , 2020, 94, e1190-e1200.	1.1	30
116	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
117	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2022, 47, 1128-1136.	5.4	30
118	Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [18F]fluoroethoxybenzovesamicol. <i>Behavioural Brain Research</i> , 2015, 278, 107-114.	2.2	29
119	Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease. <i>Human Brain Mapping</i> , 2018, 39, 971-984.	3.6	29
120	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 859-869.	2.8	29
121	White Matter Abnormalities and Structural Hippocampal Disconnections in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e74776.	2.5	28
122	Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 143-148.	3.0	28
123	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5989-6001.	7.9	28
124	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. <i>NeuroImage</i> , 2004, 22, 1076-1083.	4.2	27
125	Correlation between serotonin synthesis and 5-HT1A receptor binding in the living human brain: A combined β -[11C]MT and [18F]MPPF positron emission tomography study. <i>NeuroImage</i> , 2008, 42, 850-857.	4.2	27
126	In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. <i>Translational Neurodegeneration</i> , 2014, 3, 6.	8.0	27

#	ARTICLE	IF	CITATIONS
127	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 503-512.	0.5	27
128	Impact of the biological definition of Alzheimer's disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?. <i>Translational Neurodegeneration</i> , 2018, 7, 12.	8.0	27
129	Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. <i>Alzheimer's and Dementia</i> , 2019, 15, 951-960.	0.8	27
130	Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 747-756.	2.6	26
131	Design, construction, and validation of an MRI-compatible vibrotactile stimulator intended for clinical use. <i>Journal of Neuroscience Methods</i> , 2009, 184, 129-135.	2.5	24
132	4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, S1-S8.	0.5	24
133	Common Effects of Amnesic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 242.	3.4	24
134	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1021-1030.	6.4	24
135	Cholinergic Potentiation Alters Perceptual Eye Dominance Plasticity Induced by a Few Hours of Monocular Patching in Adults. <i>Frontiers in Neuroscience</i> , 2019, 13, 22.	2.8	24
136	Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S3.	6.2	23
137	Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4-Aza-2-oxindole Scaffold as Trk PET Imaging Agents. <i>ACS Chemical Neuroscience</i> , 2015, 6, 260-276.	3.5	23
138	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 1.	8.0	23
139	Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [¹¹ C]ABP688 Positron-Emission Tomography (PET) Imaging. <i>Cerebral Cortex</i> , 2016, 26, 4170-4179.	2.9	22
140	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 875-887.	0.8	22
141	Prevention strategies for Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2012, 1, 13.	8.0	21
142	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [¹⁸ F]THK5351 uptake in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 24, 102091.	2.7	21
143	Regional Amyloid- β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Dementia. <i>Molecular Neurobiology</i> , 2019, 56, 4916-4924.	4.0	21
144	Brain regional [¹¹ C]methyl-L-tryptophan trapping, used as an index of 5-HT synthesis, in healthy adults: absence of an age effect. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1254-1264.	6.4	20

#	ARTICLE	IF	CITATIONS
145	Use of Biomarkers in Clinical Trials of Alzheimer Disease. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 313-325.	3.8	20
146	Impact of scale space search on age- and gender-related changes in MRI-based cortical morphometry. <i>Human Brain Mapping</i> , 2013, 34, 2113-2128.	3.6	20
147	Towards tropomyosin-related kinase B (TrkB) receptor ligands for brain imaging with PET: Radiosynthesis and evaluation of 2-(4-[¹⁸ F]fluorophenyl)-7,8-dihydroxy-4H-chromen-4-one and 2-(4-([N-methyl- ¹¹ C]-dimethylamino)phenyl)-7,8-dihydroxy-4H-chromen-4-one. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7816-7829.	3.0	20
148	A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6897-6910.	6.4	20
149	Cholinergic Potentiation Improves Perceptual-Cognitive Training of Healthy Young Adults in Three Dimensional Multiple Object Tracking. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 128.	2.0	20
150	MDMA-evoked changes in cerebral blood flow in living porcine brain: Correlation with hyperthermia. <i>Synapse</i> , 2004, 53, 214-221.	1.2	19
151	Development of subnanomolar radiofluorinated (2-pyrrolidin-1-yl)imidazo[1,2-b]pyridazine pan-Trk inhibitors as candidate PET imaging probes. <i>MedChemComm</i> , 2015, 6, 2184-2193.	3.4	19
152	Proximity to Parental Symptom Onset and Amyloid- β Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 608.	9.0	19
153	First-in-Human Brain Imaging of [¹⁸ F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2697-2702.	3.5	19
154	PET imaging of freely moving interacting rats. <i>NeuroImage</i> , 2019, 191, 560-567.	4.2	19
155	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12154.	3.7	19
156	PET imaging with [¹⁸ F]fluoroethoxybenzovesamicol ([¹⁸ F]FEOBV) following selective lesion of cholinergic pedunclopontine tegmental neurons in rat. <i>Nuclear Medicine and Biology</i> , 2014, 41, 96-101.	0.6	18
157	PET/CT of Dementia. <i>American Journal of Roentgenology</i> , 2018, 211, 246-259.	2.2	18
158	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S8.	6.2	17
159	Test-retest variability of [¹¹ C]ABP688 estimates of metabotropic glutamate receptor subtype 5 availability in humans. <i>Synapse</i> , 2018, 72, e22041.	1.2	17
160	Diagnostic Approach of Early-Onset Dementia with Negative Family History: Implications from Two Cases of Early-Onset Alzheimer's Disease with De Novo PSEN1 Mutation. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 551-558.	2.6	17
161	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , 2019, 10, 1398.	3.5	17
162	In vivo metabotropic glutamate receptor type 5 abnormalities localize the epileptogenic zone in mesial temporal lobe epilepsy. <i>Annals of Neurology</i> , 2019, 85, 218-228.	5.3	17

#	ARTICLE	IF	CITATIONS
163	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021, 10, 11.	8.0	17
164	18F-MK-6240 tau-PET in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1763-1772.	7.6	17
165	MicroPET imaging of 5-HT1A receptors in rat brain: a test-retest [18F]MPPF study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 53-62.	6.4	16
166	Role of emerging neuroimaging modalities in patients with cognitive impairment: a review from the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S4.	6.2	16
167	The prevalence and biomarkers characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 107-113.	3.7	16
168	Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 162-166.	2.2	16
169	Is ApoE ϵ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?. <i>Translational Neurodegeneration</i> , 2016, 5, 20.	8.0	15
170	Constrained instruments and their application to Mendelian randomization with pleiotropy. <i>Genetic Epidemiology</i> , 2019, 43, 373-401.	1.3	15
171	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	3.3	15
172	Interactive rather than independent effect of <i>APOE</i> and sex potentiates tau deposition in women. <i>Brain Communications</i> , 2021, 3, fcab126.	3.3	15
173	Stability of \pm -[11C]methyl-I-tryptophan brain trapping in healthy male volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1199-1204.	6.4	14
174	COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMER'S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2016, 3, 1-9.	2.7	14
175	Clozapine induces astrocyte-dependent FDG-PET hypometabolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2251-2264.	6.4	14
176	Robust S1, S2, and thalamic activations in individual subjects with vibrotactile stimulation at 1.5 and 3.0 T. <i>Human Brain Mapping</i> , 2009, 30, 1328-1337.	3.6	13
177	Concordance between in vivo and postmortem measurements of cholinergic denervation in rats using PET with [18F]FEOBV and choline acetyltransferase immunohistochemistry. <i>EJNMMI Research</i> , 2013, 3, 70.	2.5	13
178	Machine Learning in Nuclear Medicine: Part 2 - Neural Networks and Clinical Aspects. <i>Journal of Nuclear Medicine</i> , 2021, 62, 22-29.	5.0	13
179	TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation. <i>Biochemical Pharmacology</i> , 2010, 80, 1572-1579.	4.4	12
180	Remodeling of Neuronal Circuits After Reach Training in Chronic Capsular Stroke. <i>Neurorehabilitation and Neural Repair</i> , 2016, 30, 941-950.	2.9	12

#	ARTICLE	IF	CITATIONS
181	Motion compensation for fully 4D PET reconstruction using PET superset data. <i>Physics in Medicine and Biology</i> , 2010, 55, 4063-4082.	3.0	11
182	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S23-S31.	2.6	11
183	Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 52.	4.2	11
184	Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	11
185	Epistasis analysis links immune cascades and cerebral amyloidosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 227.	7.2	10
186	Time-efficient and convenient synthesis of [¹⁸ F]altanserin for human PET imaging by a new work-up procedure. <i>Applied Radiation and Isotopes</i> , 2009, 67, 2040-2043.	1.5	9
187	Sensory-parietal cortical stimulation improves motor recovery in severe capsular infarct. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 2211-2222.	4.3	9
188	Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 12-21.	2.4	9
189	Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. <i>Pharmaceuticals</i> , 2019, 12, 7.	3.8	9
190	Cholinergic Modulation of Binocular Vision. <i>Journal of Neuroscience</i> , 2020, 40, 5208-5213.	3.6	9
191	Dynamic ¹ H MRS for detection of ¹³ C labeled glucose metabolism in the human brain at 3T. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 1140-1151.	3.0	9
192	CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. <i>Neurology: Genetics</i> , 2018, 4, e216.	1.9	8
193	A simplified radiosynthesis of [¹⁸ F]MK6240 for tau PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 109-114.	1.0	8
194	Efficient radiosynthesis and preclinical evaluation of [¹⁸ F]FOMPyD as a positron emission tomography tracer candidate for TrkB/C receptor imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2020, 63, 144-150.	1.0	8
195	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 788-801.	4.3	8
196	Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease. <i>European Journal of Neurology</i> , 2022, 29, 1324-1334.	3.3	8
197	Principal component of explained variance: An efficient and optimal data dimension reduction framework for association studies. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1331-1350.	1.5	7
198	Topographical distribution of A β ² predicts progression to dementia in A β ² positive mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12037.	2.4	7

#	ARTICLE	IF	CITATIONS
199	Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E1-E13.	2.4	7
200	FE0BVâ€PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. <i>Journal of Neuroimaging</i> , 2021, 31, 1077-1081.	2.0	7
201	Amyloidâ€dependent and amyloidâ€independent effects of Tau in individuals without dementia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2083-2092.	3.7	7
202	Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia. <i>ELife</i> , 2022, 11, .	6.0	7
203	Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimerâ€™s Disease Spectrum. <i>Molecular Neurobiology</i> , 2019, 56, 8336-8344.	4.0	6
204	No apparent effect of naproxen on <scp>CSF</scp> markers of innate immune activation. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1127-1133.	3.7	6
205	Artificial intelligence for molecular neuroimaging. <i>Annals of Translational Medicine</i> , 2021, 9, 822-822.	1.7	6
206	Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 288-293.	0.9	6
207	Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1211-1213.	2.8	5
208	Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 615-618.	0.8	5
209	CCCDT5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12098.	3.7	5
210	Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common Marmoset. <i>Neuroscience</i> , 2022, 480, 143-154.	2.3	5
211	Soluble amyloid-beta isoforms predict downstream Alzheimerâ€™s disease pathology. <i>Cell and Bioscience</i> , 2021, 11, 204.	4.8	5
212	Motion-compensated fully 4D PET reconstruction using PET data supersets. , 2009, , .		4
213	Towards the PET radiotracer for p75 neurotrophin receptor: [11C]LM11A-24 shows biological activity in vitro, but unfavorable ex vivo and in vivo profile. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4759-4765.	3.0	4
214	Suicidal ideation is common in autosomal dominant Alzheimer's disease atâ€risk persons. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 60-68.	2.7	4
215	Preliminary Evaluations of [11C]Verubulin: Implications for Microtubule Imaging With PET. <i>Frontiers in Neuroscience</i> , 2021, 15, 725873.	2.8	4
216	Wrappers Feature Selection in Alzheimer's Biomarkers Using kNN and SMOTE Oversampling. <i>TeMa</i> , 2017, 18, 15.	0.1	4

#	ARTICLE	IF	CITATIONS
217	Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12085.	3.7	4
218	Radiosynthesis and <i>In Vivo</i> Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1382-1394.	3.5	4
219	Development of fMRI techniques for planning in functional neurosurgery for Parkinson's disease. , 2008, , .		3
220	Disclosure of results to participants in dementia research. <i>Nature Reviews Neurology</i> , 2013, 9, 608-609.	10.1	3
221	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. <i>Future Neurology</i> , 2014, 9, 597-613.	0.5	3
222	How Can We Improve Transfer of Outcomes from Randomized Clinical Trials to Clinical Practice with Disease-Modifying Drugs in Alzheimer's Disease?. <i>Neurodegenerative Diseases</i> , 2014, 13, 197-199.	1.4	3
223	Optimal use of cholinergic drugs in Alzheimer's disease. <i>Brain</i> , 2018, 141, e68.	7.6	3
224	CCCDT5: research diagnostic criteria for Alzheimer's Disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12036.	3.7	3
225	PET Imaging of Perceptual Learning-Induced Changes in the Aged Rodent Cholinergic System. <i>Frontiers in Neuroscience</i> , 2019, 13, 1438.	2.8	3
226	Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia. <i>NeuroImage: Clinical</i> , 2021, 29, 102552.	2.7	3
227	In vivo hippocampal cornu ammonis 3 glutamatergic abnormalities are associated with temporal lobe epilepsy surgery outcomes. <i>Epilepsia</i> , 2021, 62, 1559-1568.	5.1	3
228	Imaging biomarkers for amyloid: a new generation of probes and what lies ahead. <i>International Psychogeriatrics</i> , 2014, 26, 703-707.	1.0	2
229	Le diagnostic précoce de la maladie d'Alzheimer: panacée ou catastrophe?. <i>Ethics, Medicine and Public Health</i> , 2015, 1, 151-154.	0.9	2
230	Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ϵ 4, and Cognitive Impairment. <i>Neurology</i> , 2021, 97, 609-609.	1.1	2
231	Dosimetry of PET Tracers in Mice Using microPET Scans as an Input Function. , 0, , .		1
232	Amyloid imaging in Alzheimer's disease: a potential new era of personalized medicine?. <i>Translational Neuroscience</i> , 2014, 5, .	1.4	1
233	IC-P-012: Should a global or a regional measure of amyloidosis be used in a longitudinal study?. , 2015, 11, P19-P19.		1
234	A dataset of multiresolution functional brain parcellations in an elderly population with no or mild cognitive impairment. <i>Data in Brief</i> , 2016, 9, 1122-1129.	1.0	1

#	ARTICLE	IF	CITATIONS
235	Phantom bedside intruder in Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 91-93.	0.4	1
236	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
237	Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET. <i>NeuroImage</i> , 2004, 22, 1076-1076.	4.2	0
238	Radiosynthesis of <i>cis</i> -[¹²⁴ I]iodo-L-proline as a prototype probe for imaging anterograde axoplasmic transport systems using positron emission tomography (PET). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2007, 50, 636-637.	1.0	0
239	Accelerated microPET Transmission Imaging. <i>IEEE Transactions on Nuclear Science</i> , 2008, 55, 2501-2507.	2.0	0
240	Introduction to the diagnosis of dementia. , 0, , 1-5.		0
241	Young man with slow cognitive decline. , 0, , 277-281.		0
242	4e Conférence canadienne consensuelle sur le diagnostic et le traitement de la démence. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, S1-S8.	0.5	0
243	IC-P-176: EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNO-RESPONSE. , 2014, 10, P98-P99.		0
244	P1-049: EPISTASIS ANALYSES INDICATE ASSOCIATION BETWEEN CEREBRAL AMYLOID DEPOSITION AND GENES INVOLVED IN IMMUNORESPONSE. , 2014, 10, P321-P321.		0
245	P3-133: Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study. , 2015, 11, P674-P675.		0
246	P4-097: Should a global or a regional measure of amyloidosis be used in a longitudinal study?. , 2015, 11, P811-P811.		0
247	FTS-04-03: Clinical utility of amyloid PET in the differential diagnosis of atypical dementias and its impact on caregivers. , 2015, 11, P264-P264.		0
248	IC-P-011: Comparison of global and voxel-based diagnostic classification using [18 F]florbetapir ROC estimates. , 2015, 11, P18-P19.		0
249	IC-P-027: Dynamics of longitudinal biomarker changes in the McGill-R-Thy1-APP RAT. , 2015, 11, P27-P28.		0
250	IC-P-026: Amyloidosis induces reorganization of the hippocampal metabolic network. , 2015, 11, P27-P27.		0
251	P1-036: Dynamics of longitudinal biomarker changes in the McGill-R-Thy1-APP rat. , 2015, 11, P350-P351.		0
252	P3-180: Comparison of global and voxel-based diagnostic classification using [18 F]florbetapir ROC estimates. , 2015, 11, P699-P699.		0

#	ARTICLE	IF	CITATIONS
253	IC-P-155: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24-months follow-up in cognitively normal subjects. , 2015, 11, P104-P104.		0
254	P1-159: Amyloidosis induces reorganization of the hippocampal metabolic network. , 2015, 11, P405-P406.		0
255	P1-177: Extensive white matter burden represents a new radiological phenotype in a distinct population of ad patients. , 2015, 11, P412-P413.		0
256	O5-01-06: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24 months' follow-up in cognitively normal subjects. , 2015, 11, P314-P315.		0
257	ICâ€Pâ€027: Amyloidâ€Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P28.	0.8	0
258	ICâ€Pâ€025: [¹⁸ F]Florbetapir Roc Curve at Every Voxel Revels a Wide Range of Cortical Suvr Cutâ€Offs. Alzheimer's and Dementia, 2016, 12, P27.	0.8	0
259	P1â€251: Synergism between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P504.	0.8	0
260	P1â€282: Voxelâ€Wise Logistic Regression Improves Prediction Accuracy for Developing Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P527.	0.8	0
261	ICâ€Pâ€086: Amyloidâ€ ² and Hyperphosphorylated TAU Synergy Drives Clinical Progression to Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P66.	0.8	0
262	ICâ€Pâ€099: Synergism Between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P75.	0.8	0
263	P2-093: Polymorphism in Cytochrome P450 Gene is Associated with Alzheimerâ€™s Pathology. , 2016, 12, P646-P646.		0
264	IC-P-101: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in AD Transgenic Rat Model. , 2016, 12, P77-P77.		0
265	ICâ€Pâ€157: Novel Toolbox for Performing Voxelâ€Wise Generalized Linear Regression With Multiple Volumetric Covariates in Longitudinal Data. Alzheimer's and Dementia, 2016, 12, P116.	0.8	0
266	P3â€221: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in Alzheimer's Disease Transgenic Rat Model. Alzheimer's and Dementia, 2016, 12, P910.	0.8	0
267	IC-P-159: Voxel-Wise Logistic Regression Improves Prediction Accuracy for Developing AD. , 2016, 12, P117-P118.		0
268	P3â€251: Novel Toolbox for Performing Voxelâ€Wise Generalized Linear Regression with Multiple Volumetric Covariates in Longitudinal Data. Alzheimer's and Dementia, 2016, 12, P925.	0.8	0
269	O5â€02â€06: The Association between white Matter Hyperintensities and Memory Impairment Depends on Pâ€TAU Levels in a Highâ€Risk Cohort of Aging Cognitively Normal Persons. Alzheimer's and Dementia, 2016, 12, P381.	0.8	0
270	P4â€310: The Effect of Lumbar Puncture on the Retention of the Preventâ€ad Cohort ad. Alzheimer's and Dementia, 2016, 12, P1152.	0.8	0

#	ARTICLE	IF	CITATIONS
271	P2-053: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. , 2016, 12, P627-P628.		0
272	Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 2017, 89, 1931.2-1931.	1.1	0
273	[P4â€“506]: COMPARISON BETWEEN MONOAMINE OXIDASE B INHIBITION ON THE UPTAKE OF [¹⁸ F]THK5351. Alzheimer's and Dementia, 2017, 13, P1533.	0.8	0
274	[P4â€“566]: ASSESSING THE IMPACT OF INFLAMMATION ON LIMBIC CIRCUITRY AND ITS ROLE IN DEPRESSION IN OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P1569.	0.8	0
275	Mapping the progression of vascular CSF biomarkers in pre-symptomatic â€œat-riskâ€ healthy subjects in the PREVENT-AD program. Journal of the Neurological Sciences, 2017, 381, 676.	0.6	0
276	[O2â€“14â€“O2]: PRECLINICAL ASSESSMENT OF KALâ€ABP TARGET ENGAGEMENT AND EFFICACY USING PET, MRI AND CSF BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P591.	0.8	0
277	Neuroinflammation imposes vulnerability to tau propagation. Alzheimer's and Dementia, 2020, 16, e039814.	0.8	0
278	Use of Animal Models in Molecular Imaging. Contrast Media and Molecular Imaging, 2020, 2020, 1-2.	0.8	0
279	Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada. Canadian Journal of Neurological Sciences, 2021, 48, 312-320.	0.5	0
280	Elderly Man Repeating Questions about Upcoming Appointments. , 2021, , 14-17.		0
281	Dementia and Bioethics. Mental Health and Illness Worldwide, 2016, , 1-13.	0.1	0
282	Dementia and Bioethics. Mental Health and Illness Worldwide, 2017, , 141-153.	0.1	0
283	Clinical Meaningfulness of Biomarker Endpoints in Alzheimerâ€™s Disease Research. Neuromethods, 2018, , 235-248.	0.3	0
284	Highâ€yielding, automated radiosynthesis of [¹¹ C]martinostat using [¹¹ C]methyl triflate. Journal of Labelled Compounds and Radiopharmaceuticals, 2022, , .	1.0	0
285	Tauâ€load in the lingual gyrus impacts anxiety levels during the COVIDâ€19 pandemic in participants of longitudinal observational studies in aging. Alzheimer's and Dementia, 2021, 17, .	0.8	0
286	Tau accumulation using [¹⁸ F]MK6240 PET is associated with increase in executive dysfunction in prodromal AD. Alzheimer's and Dementia, 2021, 17, .	0.8	0